CABALETTA BIO INC's ticker is CABA and the CUSIP is 12674W109. A total of 61 filers reported holding CABALETTA BIO INC in Q3 2021. The put-call ratio across all filers is 0.27 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $4,562,485 | +64.8% | 299,769 | +39.8% | 0.00% | 0.0% |
Q2 2023 | $2,768,962 | +734.0% | 214,482 | +434.2% | 0.00% | – |
Q1 2023 | $332,016 | +5.0% | 40,147 | +17.4% | 0.00% | – |
Q4 2022 | $316,313 | +1564.8% | 34,196 | +16.7% | 0.00% | – |
Q3 2022 | $19,000 | -38.7% | 29,307 | 0.0% | 0.00% | – |
Q2 2022 | $31,000 | -47.5% | 29,307 | 0.0% | 0.00% | – |
Q1 2022 | $59,000 | -46.8% | 29,307 | 0.0% | 0.00% | – |
Q4 2021 | $111,000 | -63.5% | 29,307 | +17.4% | 0.00% | – |
Q3 2021 | $304,000 | +38.8% | 24,970 | -2.2% | 0.00% | – |
Q2 2021 | $219,000 | -84.8% | 25,521 | -80.4% | 0.00% | – |
Q1 2021 | $1,445,000 | -17.0% | 130,168 | -6.8% | 0.00% | – |
Q4 2020 | $1,742,000 | +11.0% | 139,625 | -3.5% | 0.00% | – |
Q3 2020 | $1,569,000 | +7.8% | 144,699 | +10.8% | 0.00% | – |
Q2 2020 | $1,455,000 | +104.4% | 130,626 | +34.1% | 0.00% | – |
Q1 2020 | $712,000 | -24.2% | 97,435 | +44.9% | 0.00% | – |
Q4 2019 | $939,000 | – | 67,231 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Lynx1 Capital Management LP | 2,106,000 | $32,053,320 | 21.20% |
COMMODORE CAPITAL LP | 2,525,753 | $38,441,961 | 4.49% |
Bain Capital Life Sciences Investors, LLC | 2,000,000 | $30,440,000 | 3.40% |
VR Adviser, LLC | 1,973,253 | $30,032,911 | 3.16% |
Cormorant Asset Management, LP | 2,879,424 | $43,824,833 | 2.56% |
Velan Capital Investment Management LP | 150,000 | $2,283,000 | 1.84% |
Redmile Group, LLC | 1,774,252 | $27,004,115 | 1.28% |
TCG Crossover Management, LLC | 486,795 | $7,409,020 | 1.09% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,340,118 | $35,616,596 | 0.78% |
Integral Health Asset Management, LLC | 330,000 | $5,022,600 | 0.70% |